Treatments for fragile X syndrome: A closer look at the data

Developmental Disabilities Research Reviews

Volumn 15, Issue 4, 2009, Pages 353-360

  Hall, Scott S ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Behavioral treatment; FMR1 gene; Fragile X syndrome; Psychopharmacology

Indexed keywords

6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CENTRAL STIMULANT AGENT; DEXAMPHETAMINE; DONEPEZIL; FENOBAM; FOLINIC ACID; FRAGILE X MENTAL RETARDATION PROTEIN; LEVACECARNINE; LITHIUM; MELATONIN; MEMANTINE; METABOTROPIC RECEPTOR ANTAGONIST; METHYLPHENIDATE; NEUROLEPTIC AGENT; OXYTOCIN; PLACEBO; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ADAPTIVE BEHAVIOR; ANOREXIA; ANXIETY; ARTICLE; AUTISM; BEHAVIOR DISORDER; BEHAVIOR THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DIZZINESS; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG WITHDRAWAL; DYSPNEA; EMOTIONAL DISORDER; FRAGILE X SYNDROME; HALLUCINATION; HUMAN; INTELLECT; IRRITABILITY; LIVER INJURY; MENTAL INSTABILITY; NOCTURNAL ENURESIS; NONHUMAN; OCCUPATIONAL THERAPY; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SEDATION; SIDE EFFECT; SPECIAL EDUCATION; SPEECH THERAPY; WEIGHT GAIN;

EID: 73849096178     PISSN: 19405510     EISSN: 10982779     Source Type: Journal    
DOI: 10.1002/ddrr.78     Document Type: Article

References (48)

1. Bear MF, Huber KM, Warren ST. 2004. The mGluR theory of fragile X mental retardation. Trends Neurosci 27:370-377.
2. Berry-Kravis E, Potanos K. 2004. Psychopharmacology in fragile X syndrome-present and future. Ment Retard Dev Disabil Res Rev 10:42-48.
3. Berry-Kravis E, Krause SE, Block SS, et al. 2006. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol 16:525-540.
4. Berry-Kravis E, Sumis A, Kim OK, et al. 2008. Characterization of potential outcome measures for future clinical trials in fragile X syndrome. J Autism Dev Disord 38:1751-1757.
5. Berry-Kravis E, Hessl D, Coffey S, et al. 2009. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet 46:266-271.
6. Braden ML. 2002. Academic interventions. In: Hagerman RJ, Hagerman PJ, editors. Fragile X syndrome: diagnosis, treatment, and research, 3rd ed. Baltimore: The Johns Hopkins University Press. p 423-464.
7. Brown WT, Jenkins EC, Friedman E, et al. 1984. Folic acid therapy in the fragile X syndrome. Am J Med Genet 17:289-297.
8. Brown WT, Cohen IL, Fisch GS, et al. 1986. High dose folic acid treatment of fragile (X) males. Am J Med Genet 23:263-271.
9. Cohen H, Amerine-Dickens M, Smith T. 2006. Early intensive behavioral treatment: replication of the UCLA model in a community setting. J Dev Behav Pediatr 27(2 Suppl):S145-S155.
10. Cooper JO, Heron TE, Heward WI. 1987. Applied behavior analysis. Upper Saddle River, New Jersey: Prentice-Hall.
11. Crawford DC, Meadows KL, Newman JL, et al. 1999. Prevalence and phenotype consequence of FRAXA and FRAXE alleles in a large, ethnically diverse, special education-needs population. Am J Hum Genet 64:495-507.
12. de Vrij FM, Levenga J, van der Linde HC, et al. 2008. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis 31:127-132.
13. Dykens EM, Hodapp RM, Finucane BM. 2000. Genetics and ment retard syndromes. Baltimore: Paul H. Brookes.
14. Epstein JLH, Riley K, Sobessky WE. 2002. The treatment of emotional and behavioral problems. In: Hagerman RJ, Hagerman PJ, editors. Fragile X syndrome: diagnosis, treatment, and research, 3rd ed. Baltimore: The Johns Hopkins University Press. p 339-362.
15. Erikson CA, Mullet JE, McDougle CJ. In press. Open-label memantine in fragile X syndrome. J Autism Dev Disord
16. Fisch GS, Cohen IL, Gross AC, et al. 1988. Folic acid treatment of fragile X males: a further study. Am J Med Genet 30:393-399.
17. Froster-Iskenius U, Bodeker K, Oepen T, et al. 1986. Folic acid treatment in males and females with fragile-(X)-syndrome. Am J Med Genet 23:273-289.
18. Gillberg C, Wahlstrom J, Johansson R, et al. 1986. Folic acid as an adjunct in the treatment of children with the autism fragile-X syndrome (AFRAX). Dev Med Child Neurol 28:624-627.
19. Greenough WT, Klintsova AY, Irwin SA, et al. 2001. Synaptic regulation of protein synthesis and the fragile X protein. Proc Natl Acad Sci USA 98:7101-7106.
20. Gustavson KH, Dahlbom K, Flood A, et al. 1985. Effect of folic acid treatment in the fragile X syndrome. Clin Genet 27:463-467.
21. Hagerman PJ. 2002a. FMR1 gene expression and prospects for gene therapy. In: Hagerman RJ, Hagerman PJ, editors. Fragile X syndrome: diagnosis, treatment, and research, 3rd ed. Baltimore: The Johns Hopkins University Press. p 465-494.
22. Hagerman RJ. 2002b. Medical follow-up and pharmacotherapy. In: Hagerman RJ, Hagerman PJ, editors. Fragile X syndrome: diagnosis, treatment, and research, 3rd ed. Baltimore: The Johns Hopkins University Press. p 287-338.
23. Hagerman RJ, Jackson AW, Levitas A, et al. 1986. Oral folic acid versus placebo in the treatment of males with the fragile X syndrome. Am J Med Genet 23:241-262.
24. Hagerman RJ, Murphy MA, Wittenberger MD. 1988. A controlled trial of stimulant medication in children with the fragile X syndrome. Am J Med Genet 30:377-392.
25. Hagerman RJ, Fulton MJ, Leaman A. 1994. A survey of fluoxetine therapy in fragile X syndrome. Dev Brain Dysfunct 7:155-164.
26. Hagerman RJ, Riddle JE, Roberts LS. 1995. Survey of efficacy of clonidine in fragile X syndrome. Dev Brain Dysfunct 8:336-344.
27. Hall SS, Debernardis GM, Reiss AL. 2006. The acquisition of stimulus equivalence in individuals with fragile X syndrome. J Intellect Disabil Res 50 (Part 9):643-651.
28. Hall SS, Maynes NP, Reiss AL. 2009. Using percentile schedules to increase eye contact duration in children with fragile X syndrome. J Appl Behav Anal 42:171-176.
29. Kesler SR, Lightbody AA, Reiss AL. 2009. Cholinergic dysfunction in fragile X syndrome and potential intervention: a preliminary 1H MRS study. Am J Med Genet A 149A:403-407.
30. Lejeune J, Rethore MO, de Blois MC, et al. 1984. Trial of folic acid treatment in fragile X syndrome. Ann Genet 27:230-232.
31. Lovaas OI. 1987. Behavioral treatment and normal educational and intellectual functioning in young autistic children. J Consult Clin Psychol 55:3-9.
32. Martin G, Pear J. 2003. Behavior modification: what it is and how to do it. New Jersey: Prentice Hall.
33. Martin JP, Bell J. 1943. A pedigree of mental defect showing sex-linkage. J Neurol Psychiatry 6:154-157.
34. McEachin JJ, Smith T, Lovaas OI. 1993. Longterm outcome for children with autism who received early intensive behavioral treatment. Am J Ment Retard 97:359-372; discussion 373-391.
35. Rattazzi MC, LaFauci G, Brown WT. 2004. Prospects for gene therapy in the fragile X syndrome. Ment Retard Dev Disabil Res Rev 10:75-81.
36. Reiss AL, Hall SS. 2007. Fragile X syndrome: assessment and treatment implications. Child Adolesc Psychiatr Clin N Am 16:663-675.
37. Remington B, Hastings RP, Kovshoff H, et al. 2007. Early intensive behavioral intervention: outcomes for children with autism and their parents after two years. Am J Ment Retard 112:418-438.
38. Romero-Zerbo Y, Decara J, el Bekay R, et al. 2009. Protective effects of melatonin against oxidative stress in Fmr1 knockout mice: a therapeutic research model for the fragile X syndrome. J Pineal Res 46:224-234.
39. Scharfenaker S, O'Connor R, Stackhouse T, et al. 2002. An integrated approach to intervention. In: Hagerman RJ, Hagerman PJ, editors. Fragile X syndrome: diagnosis, treatment, and research, 3rd ed. Baltimore: The Johns Hopkins University Press. p 363-427.
40. Strom CM, Brusca RM, Pizzi WJ. 1992. Doubleblind, placebo-controlled crossover study of folinic acid (Leucovorin) for the treatment of fragile X syndrome. Am J Med Genet 44:676-682.
41. Torrioli MG, Vernacotola S, Mariotti P, et al. 1999. Double-blind, placebo-controlled study of L-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome. Am J Med Genet 87:366-368.
42. Torrioli MG, Vernacotola S, Peruzzi L, et al. 2008. A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet A 146:803-812.
43. Turner G, Webb T, Wake S, et al. 1996. Prevalence of fragile X syndrome. Am J Med Genet 64:196-197.
44. Valdovinos MG, Parsa RA, Alexander ML. 2009. Results of a nation-wide survey evaluating psychotropic medication use in fragile X syndrome. J Dev Psychical Disabil 21:23-37.
45. Verkerk AJ, Pieretti M, Sutcliffe JS, et al. 1991. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65:905-914.
46. Weiskop S, Richdale A, Matthews J. 2005. Behavioural treatment to reduce sleep problems in children with autism or fragile X syndrome. Dev Med Child Neurol 47:94-104.
47. Wirojanan J, Jacquemont S, Diaz R, et al. 2009. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med 5:145-150.
48. Zarcone J, Napolitano D, Valdovinos M. 2008. Measurement of problem behaviour during medication evaluations. J Intellect Disabil Res 52:1015-1028.